Search
sipuleucel-T (Provenge)
Indications:
- metastatic prostate cancer
Procedure:
- leukapheresis
- in vitro stimulation to a protein found in most prostate cancer cells linked to an adjuvant
- the stimulated leukocytes are returned to the patient
- 3 doses at 1 week intervals
Mechanism of action:
- autologous cellular immunotherapy
Notes:
- cost (2010) $93,000 compared with $18,000 for docetaxel
- increases life expectancy from 22 to 26 months
General
biological response modifier; immune factor; immunomodulator; biomodulator
References
- Prescriber's Letter 17(6): 2010
Provenge (Sipuleucel-T) for Advanced Prostate Cancer
Detail-Document#: 260612
(subscription needed) http://www.prescribersletter.com
- Nelson R
onger Survival With Sipuleucel-T in Advanced Prostate Cancer.
Medscape - Nov 09, 2020
https://www.medscape.com/viewarticle/940590
- McKay RR, Hafron JM, Ferro C et al
A Retrospective Observational Analysis of Overall Survival with
Sipuleucel-T in Medicare Beneficiaries Treated for Advanced
Prostate Cancer.
Adv Ther 2020. 37, 4910-4929
PMID: 33029725 PMCID: PMC7596004 Free PMC article
https://link.springer.com/article/10.1007/s12325-020-01509-5